Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Blondeaux Eva, Sonnenblick Amir, Agostinetto Elisa, Bas Raphaëlle, Kim Hee J, Franzoi Maria A, Bernstein-Molho Rinat, Linn Sabine, Kwong Ava, Pogoda Katarzyna, Balmana Judith, Smeets Ann, Bajpai Jyoti, Moore Halle C F, Partridge Ann H, Phillips Kelly-Anne, Toss Angela, Rousset-Jablonski Christine, Peccatori Fedro A, Renaud Tiphaine, Ferrari Alberta, Paluch-Shimon Shani, Mando Pablo, Lee Jeong E, Fruscio Robert, Cui Wanda, Wong Stephanie M, Vernieri Claudio, Ruddy Kathryn J, Dieci Maria V, Matikas Alexios, Rozenblit Mariya, Guven Deniz C, Lee Minna, Villarreal-Garza Cynthia, Hwang Shelley E, De Marchis Laura, Puglisi Fabio, Kemp Zoe, Meireles Pedro A, Parokonnaya Anastasia, Werutsky Gustavo, Okano Maiko, Azim Hatem A, Mati Kleida, Rosenberg Shoshana, Gelber Richard, Boni Luca, Lambertini Matteo
Аннотация
METHODS: The BRCA BCY Collaboration is an international, hospital-based, retrospective cohort study, conducted at 109 centres in five continents, including women harbouring germline BRCA1, BRCA2, or both, pathogenic or likely pathogenic variants and diagnosed with stage I-III invasive breast cancer at the age of 40 years or younger between Jan 1, 2000, and Dec 31, 2020. The primary objectives of the present analysis were to determine the association between RRM or RRSO and overall survival in young BRCA carriers with breast cancer. The primary endpoint was overall survival. This study is registered with ClinicalTrials.gov, NCT03673306.
FINDINGS: Between Jan 1, 2000 and Dec 31, 2020, 5290 patients were included, of whom 3361 (63·5%) patients were BRCA1 pathogenic variant carriers, 2708 (51·2%) had node-negative, and 2421 (45·8%) hormone receptor-positive breast cancer. Of 5290 patients, 2910 (55·0%) underwent RRM, 2782 (52·6%) underwent RRSO. After a median follow-up of 8·2 years (IQR 4·7-12·8), RRM was associated with significantly better overall survival compared with no RRM (adjusted HR [aHR] 0·65, 95% CI 0·53-0·78; 20-year restricted mean overall survival time 17·89 years [95% CI 17·61-18·17] with RRM vs 16·65 years [16·38-16·92] without RRM). RRSO was also associated with significantly better overall survival compared with no RRSO (aHR 0·58, 95% CI 0·48-0·71; 20-year restricted mean overall survival time 17·73 years [95% CI 17·43-18·03] with RRSO vs 16·67 years [16·38-16·96] without RRSO).
INTERPRETATION: In this global cohort of BRCA carriers with previous breast cancer diagnosis at a young age, RRM and RRSO were both associated with a significant improvement in overall survival. These findings provide evidence for a tailored counselling of a unique and high-risk patient population on cancer risk management strategies.
FUNDING: Italian Association for Cancer Research.